Skip to main content
. Author manuscript; available in PMC: 2013 Sep 22.
Published in final edited form as: Am J Nephrol. 2012 Jul 26;36(2):168–174. doi: 10.1159/000341273

Table 1.

Baseline characteristics according to mannitol administration

No Mannitol Mannitol pa
n=54 n=48

Male (%) 66.7 72.9 0.49
Age (years) 63.7 ±13.9 60.4 ±17.3 0.29
Black (%) 18.5 10.4 0.25
DM (%) 50.0 37.5 0.20
CHF (%) 24.1 20.8 0.70
Pre-dialysis weight (kg) 83.6 ±19.5 83.6 ±23.3 >0.9
Access (%)
AVF 30.8 14.9 0.06
AVG 0.0 2.1 0.29
Catheter 69.2 83.0 0.11
Mean Pre-dialysis SBP
(mmHg)
141.3 ±30.6 141.8 ±26.7 >0.9
Mean pre-dialysis DBP
(mmHg)
72.3 ±17.6 70.4 ±16.5 0.59
Serum sodium (mmol/L) 135.6 ±5.4 137.4 ±6.6 0.15
Serum albumin (g/dL) 3.2 ±0.7 3.4 ±0.7 0.21
Serum creatinine (mg/dL) 7.1 ±3.5 7.5 ±3.6 0.59
Hemoglobin (g/dL) 9.1 ±1.4 9.5 ±1.8 0.26
Any BP medication (%) 83.3 72.9 0.20
ESKD (%) 72.2 56.2 0.09
UF volume (l) 0.8 (0.0, 1.0) 0.8 (0.0, 1.5) 0.85
a

P value for global difference; significance testing was by t-test or Wilcoxon rank-sum test for continuous variables and Chi2 test for dichotomous variables.

Parameters are presented as mean ±standard deviation or median (inter-quartile range).

DM, diabetes mellitus; CHF, congestive heart failure; AVF, arteriovenous fistula; AVG, arteriovenous graft; SBP, systolic blood pressure; DBP, diastolic blood pressure; ESKD, End-stage kidney disease (vs reference of acute kidney injury requiring hemodialysis); UF, ultrafiltration at first session.